Shanghai Changzheng Hospital: Colorectal Neoplasms trials

The registry lists 15 Colorectal Neoplasms studies with Shanghai Changzheng Hospital as lead sponsor. 7 are open to participants now and 0 have results posted.

Early Phase 1 2Phase 1 1Phase 2 10No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal CancerRecruitingNCT07398326Phase 2
• A Dose-Expansion Trial of Intravenous HNF4α srRNA for Unresectable or Metastatic Colorectal CancerRecruitingNCT07050394Early Phase 1
• The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.RecruitingNCT06930118Phase 2
• CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal CancerRecruitingNCT06881537Phase 2
• A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α SrRNA in Treating Metastatic CRC PatientsRecruitingNCT06621173Early Phase 1
• Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal CancerRecruitingNCT06603376Phase 2
• Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver MetastasesNot yet recruitingNCT05588297Phase 2
• CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal CancerActive, not recruitingNCT07801352Phase 2
• Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)CompletedNCT04271813Phase 2
• Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal CancerStatus unknownNCT04110093Phase 1/2
• Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.Status unknownNCT03843749Not applicable
• ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation.Status unknownNCT03792568Not applicable
• Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)Status unknownNCT03727763Phase 2
• High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28Status unknownNCT03329183Phase 2
• Discovery and Validate of Multi-genetic Biomarkers for Capecitabine in Chinese Colorectal PatientsStatus unknownNCT03030508